Sandra Boenisch - 24 Sep 2026 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Reporting relationship: PFO & Treasurer
Issuer ticker: AVXL
Reported as of: 24 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Sep 2026, 21:36:32 UTC
Prior SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandra Boenisch

Filing notes and source

Key filing fact

Sandra Boenisch filed Form 4 for ANAVEX LIFE SCIENCES CORP. (AVXL) on 28 Sep 2026.

Key facts

This page summarizes Sandra Boenisch's Form 4 filing for ANAVEX LIFE SCIENCES CORP. (AVXL).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Sep 2026, 21:36.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001655366 Primary reporting owner

Boenisch Sandra

Relationship: PFO & Treasurer
Address: 630 5TH AVENUE, 20TH FLOOR, NEW YORK
Signature: /s/ Sandra Boenisch
Signature date: 28 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVXL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +20,000
Change %
Price: $0.000000^*
Shares after: 20,000
Date: 24 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $10.09
Footnotes: F1

AVXL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +25,000
Change %
Price: $0.000000^*
Shares after: 25,000
Date: 24 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $8.57
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.